- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection
-
- Takaoka Yoshinari
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Miura Kouichi
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Morimoto Naoki
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Kakizaki Satoru
- Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine
-
- Ikegami Tadashi
- Department of Gastroenterology, Ibaraki Medical Center, Tokyo Medical University
-
- Ueno Takashi
- Department of Internal Medicine, Isesaki Municipal Hospital
-
- Arai Hirotaka
- Department of Gastroenterology, Maebashi Red Cross Hospital
-
- Hatanaka Takeshi
- Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital
-
- Tahara Toshiyuki
- Department of Gastroenterology, Saiseikai Utsunomiya Hospital
-
- Murohisa Toshimitsu
- Department of Gastroenterology, Ashikaga Red Cross Hospital
-
- Namikawa Masashi
- Department of Internal Medicine, Kiryu Kosei General Hospital
-
- Naganuma Atsushi
- Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
-
- Ohtake Takaaki
- Department of Gastroenterology, International University of Health and Welfare Hospital
-
- Horiuchi Katsuhiko
- Department of Gastroenterology, Gunma Chuo Hospital, Japan Community Health care Organization
-
- Asano Takeharu
- Department of Gastroenterology, Saitama Medical Center, Jichi Medical University
-
- Kamoshida Toshiro
- Department of Gastroenterology, Hitachi General Hospital
-
- Tano Shigeo
- Department of Gastroenterology, Shin-Oyama City Hospital
-
- Fukaya Yukimura
- Department of Internal Medicine, Nasu Minami Hospital
-
- Kosone Takashi
- Department of Gastroenterology and Hepatology, Kusunoki Hospital
-
- Watanabe Shunji
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Tsukui Mamiko
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Hirosawa Takuya
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Nomoto Hiroaki
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Goka Rie
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Maeda Hiroshi
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Sato Naoto
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Isoda Norio
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
-
- Yamamoto Hironori
- Department of Medicine, Division of Gastroenterology, Jichi Medical University
Bibliographic Information
- Other Title
-
- C型非代償性肝硬変に対するソフォスブビル/ベルパタスビル12週治療の有効性と安全性
- Cガタ ヒダイショウセイ カンコウヘン ニ タイスル ソフォスブビル/ベルパタスビル 12シュウ チリョウ ノ ユウコウセイ ト アンゼンセイ
Search this article
Description
<p>In this multicenter study, we evaluated the efficacy and safety of 12-week sofosbuvir/velpatasvir (SOF/VEL) treatment. We enrolled 43 consecutive patients with decompensated cirrhosis caused by hepatitis C virus (HCV) infection, 72% and 28% of them were positive for genotype 1 and 2, respectively. At baseline, 79% of the patients were Child-Pugh (CP) class B and 19% were CP class C. All patients completed the 12-week SOF/VEL treatment without any severe adverse events. At post-treatment week 12, 41 patients achieved a sustained virological response (95%), and 21 showed improvement in CP class. The remaining two patients were lost to follow-up. Encephalopathy was a frequent adverse event (16%), but was well-controlled by outpatient management. In conclusion, 12-week SOF/VEL treatment is effective and safe for patients with decompensated cirrhosis caused by HCV infection.</p>
Journal
-
- Kanzo
-
Kanzo 61 (5), 276-278, 2020-05-01
The Japan Society of Hepatology
- Tweet
Details 詳細情報について
-
- CRID
- 1390285300156723328
-
- NII Article ID
- 130007841486
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 030387600
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed